Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-06-29. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: leukemiacellpatients mustchemotherapyradiation
  Phrases that lowered it: lymphomabloodnormaladministrationfemale
• Sponsor's past termination rate: 18.0% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 115 (lowers risk) · Sponsor's track record
• Sponsor's past trials: 423 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Drug's FAERS reports before start: 133338 (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 24.3% (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 91.1% (raises risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 26344 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma NCT01614197 · started 2015 · scored riskier than 94% of active trials completed
• Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma NCT01403415 · started 2011 · scored riskier than 38% of active trials completed
• AC220 for Children With Relapsed/Refractory ALL or AML NCT01411267 · started 2011 · scored riskier than 99% of active trials completed
• Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia NCT03515200 · started 2018 · scored riskier than 52% of active trials terminated
• Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours NCT02343718 · started 2015 · scored riskier than 45% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.